Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 500-504

  Hochster, Howard ^a   Chen, Thomas T ^a   Lu, Janice M ^a   Hills, Day ^a   Sorich, Joan ^a   Escalon, Juliet ^a   Ivy, Percy ^b   Liebes, Leonard ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ovarian cancer; Oxaliplatin; Topotecan

Indexed keywords

CISPLATIN; OXALIPLATIN; PLATINUM; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 39249084997     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.017     Document Type: Article

References (30)

1. Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donehower R.C., et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst vol 88 11 (1996) 734-741
2. ten Bokkel Huinink W., Lane S.R., and Ross G.A. International Topotecan Study Group. Long-term survival in phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15 1 (Jan 2004) 100-103
3. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 12 (1996) 3056-3061
4. Hochster H., Liebes L., Speyer J., Sorich J., Taubes B., Oratz R., et al. Effect of prolonged topotecan infusion on topoisomerase-1 levels: a phase I and pharmacodynamic study. Clin Can Res 8 (1997) 1245-1252
5. Hochster H., Wadler S., Runowicz C., Liebes L., Cohen H., Wallach R., et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol 17 8 (1999) 2553-2561
6. Hochster H.S., Plimack E.R., Mandeli J., Wadler S., Runowicz C., Goldberg G., et al. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol Oncol 100 2 (Feb 2006) 324-329 [Electronic publication ahead of print, 2005 Oct 25]
7. Mirchandani D., Hochster H., Hamilton A., Liebes L., Yee H., Curtin J.P., et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res 11 16 (2005) 5912-5919
8. Rowinsky E.K., Kaufman S.H., Baker S.D., et al. Sequences of topotecan and cisplatin: phase I pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 14 (1996) 3074-3084
9. Woynarowski JM, Chapman W, Napier C, et al. Mechanisms of action of oxaliplatin: oxaliplatin-induced lesions in cellular DNA. An Antonio (TX): Institute for Drug Development Report; 1997 Jan. Research Report.
10. Fink D., Zheng H., Nebel S., et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57 (1997) 1841-1845
11. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetaplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institutes Anticancer Drug Screen panel. Biochem Pharmocol 52 12 (Dec 24 1996) 1855-1865
12. Mathe G., Kidani Y., Segiguchi M., et al. Oxalato-platinum or 1-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43 4 (1989) 237-250
13. Chollet P., Bensmaine M.A., Brienza S., et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7 (1996) 1065-1070
14. Markman M., and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10 (1992) 513-514
15. Soulie P., Bensmaine M.A., Garrino C., et al. Oxaliplatin/cisplatin (l-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33 (1997) 1400-1406
16. Misset J.L., Chollet P.H., Vennin P.H., et al. Multicentric phase II-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide in the treatment of advanced ovarian cancer (AOC): toxicity efficacy results. Proceedings of ASCO 16 (1997) [Abstract 1266]
17. Maliepaard M.X., van Klink Y.C.F., Floor B.J.G., Ruevekamp M., and Schellens J.H.M. Platinum adduct removal in relation to schedule-dependent cytotoxicity of topotecan or SN-38 and platinum (II) and (IV) compounds in vitro. Proc. ASCO 16 (1997) [Abstract 1266]
18. Beijnen J., Smith B.R., Keijer W.J., et al. High performance liquid chromatography analysis of the new anti-tumor drug SK and F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 8 (1990) 789-794
19. Liebes L., Potmesil M., and Km T. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 4 (1998) 545-557
20. Misset J.L., Goldwasser F., Riofrio M., Gross M., Romain D., and Lokiec F. Topotecan-oxaliplatin every three weeks: a phase I and pharmacological study. Prc Am Soc Clin Onc 18 (1999) [abst 845]
21. Gordon A.N., Fleagle J.R., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 14 (Jul 15 2001) 3312-3322
22. Piccart M.J., Green J.A., and Lacave A.J. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18 6 (Mar 2000) 1193-1202
23. Bhargava P., Gammon D., and McCormick M.J. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 100 1 (Jan 1 2004) 211-212
24. Simpson A.B., Calvert P.M., Sludden J.A., et al. Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Ann Oncol 13 3 (Mar 2002) 399-402
25. Bookman M.A., McMeekin D.S., and Fracasso P.M. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 103 2 (Nov 2006) 473-478 [Electronic publication ahead of print, 2006 May 2]
26. Muggia F., Kosloff R., Liebes L., and Hochster H. Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan. Oncologist 11 5 (May 2006) 529-531
27. Mirchandani D., Hochster H., Hamilton A., et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res 11 16 (Aug 15 2005) 5912-5919
28. Gross-Goupil M., Lokiec F., Lopez G., et al. Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. Eur J Cancer 38 14 (Sep 2002) 1888-1898
29. Hutter G., Szelenyi H., Deckert P.M., Keilholz U., and Thiel E. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5FU pre-treated patients with colorectal cancer. Cancer Chemother Pharmacol 54 2 (2004) 178-184
30. Elkas J.C., Winter W.E., Chernofsky M.R., et al. A phase I trial of oxaliplatin and weekly topotecan in recurrent ovarian cancer. Gyn Oncol 104 2 (2007) 422-427